The Country

From the Right · Read · November 10, 2026

Nov 9 · The FDA orders a new warning on all GLP-1 drugs, including Ozempic and Wegovy, for a rare eye condition that can cause vision loss

New York Post: The Post leads with blindness and a 2024 study, and leaves out the drugmakers' response.

Grade C (72/100). Article: New York Post on the FDA's GLP-1 warning

Lehrer score 72/100 (starts at 85; +3 primary document linked or cited (filing, ruling, data release, statement): the FDA's Nov. 9 drug safety communication quoted: "Consider discontinuing the GLP-1 RA in patients who develop NAION"; +2 context: background or what came before: "The warning follows a 2024 study"; −6 leaves out a fact or voice the other two pieces report / one side only (rule 5/13): leaves out the drugmakers' response, which CBS News and CNBC both report (Novo Nordisk: the data "do not establish a cause-and-effect relationship"); −6 leaves out a fact or voice the other two pieces report / one side only (rule 5/13): leaves out how rare the cases were in the FDA's trial review (about 6 in 100,000), which CBS News and CNBC both report; −3 talks down to the audience: bait headline or tease the piece doesn't deliver (rule 6): headline "incurable blindness condition" for what the FDA calls a "potential increased risk of rare NAION events"; −3 entertainment framing in news: hype, stings, celebrity angle over substance (rule 16): opens with a pun: "You're going to want to keep an eye on this."). Fixed scale: 90+ A, 80s B, 70s C, 60s D, under 60 F → C.

What we checked: leaves out the drugmakers' response, which CBS News and CNBC both report (Novo Nordisk: the data "do not establish a cause-and-effect relationship"); leaves out how rare the cases were in the FDA's trial review (about 6 in 100,000), which CBS News and CNBC both report; headline "incurable blindness condition" for what the FDA calls a "potential increased risk of rare NAION events"; opens with a pun: "You're going to want to keep an eye on this."

Splits: Article: New York Post on the FDA's GLP-1 warning

Read at New York Post

Same story: CBS News, CNBC

More graded coverage

How the grades work

Dispute this grade

Disagree with our approach or a rating? Have other feedback?

Tell us what you think we got wrong, or anything else. We read every message.

Become a Founding Member. Founding members get pundit scorecards free forever.

We store your email (and your name, if you give it) only to contact you about The Country. We never sell it. To be removed, unsubscribe from any email or write to [email protected].

Follow us:
About Watch Archive Join Contact Privacy Terms RSS